WILMINGTON, DE — Enovis Corporation (NYSE: ENOV) reported solid second-quarter results, posting 7% year-over-year sales growth and raising its full-year financial guidance amid continued momentum in its orthopedic business segments.
For the quarter ended July 4, 2025, Enovis generated $565 million in net sales, driven by strong performance in its Reconstructive (Recon) segment, which rose 11% on a reported basis and 8% organically. Performance & Recovery (P&R) sales increased 5% year-over-year on a reported basis and 3% organically, reflecting stable market demand and new product traction.
Despite top-line growth, the company recorded a net loss of $37 million for the quarter, or a loss of $0.64 per share from continuing operations. Adjusted net earnings came in at $0.79 per diluted share, with adjusted EBITDA reaching $97 million, or 17.2% of sales.
CEO Damien McDonald, who took the helm earlier this year, expressed optimism about the company’s trajectory. “Our second-quarter performance reflects the strength of our diversified global portfolio and the opportunity ahead,” McDonald said, emphasizing the company’s commitment to operational discipline and long-term value creation.
Enovis also revised its full-year 2025 outlook upward. The company now expects revenue between $2.245 billion and $2.275 billion, compared to prior guidance of $2.220 billion to $2.250 billion. Adjusted EBITDA is forecasted between $392 million and $402 million, and adjusted EPS is now projected to range from $3.05 to $3.20 — an increase from the previous estimate of $2.95 to $3.10.
The updated guidance signals growing confidence in Enovis’ orthopedic platform and its ability to scale profitably, even amid a competitive healthcare landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.